FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 168 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR John Travolta Supports Olivia Newton-John As She Battles Cancer September 3, 2019 Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma December 10, 2025 FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients June 23, 2020 Man Gives Up His First-Class Seat For 88-Year-Old Woman, Makes Her... November 16, 2021 Load more HOT NEWS Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas Witness the Moment of Absolute Triumph as Baltimore Woman Is Finally... Qué debo saber sobre los programas de emparejamiento de ensayos clínicos... The Doctor Will See You Now…On the Screen
